Relationship between the presence of the BRCA mutation (BReast Cancer) and outcomes is unclear in high-risk early breast cancers (BC). This study is a multi-center retrospective cohort of patients treated in region Franche-Comté for an early BC by neoadjuvant and/or adjuvant chemotherapy. The primary aim was to describe clinical and pathological characteristics considering BRCA mutated (BRCAm) patients versus BRCA wild type (BRCAwt) patients or untested patients. The second objective was to assess the prognostic impact of germinal BRCAm in this high-risk population.
Study Type
OBSERVATIONAL
Enrollment
2,295
The genetic testing was performed according interregional consensus (Manchester score \> or = 16) on blood sample using classical chain-termination (Sanger sequencing) and multiplex ligation-dependant probe amplification to search large rearrangements.
University Hospital Jean Minjoz
Besançon, Franche-Comté, France
Age of diagnosis
The date from the date of birth to the date of pathological diagnosis (Years)
Time frame: one day
Pathological tumor size
Pathological tumoral size after partial or complete surgery Pathological size in millimeters after complete surgery
Time frame: one day
Pathological nodal involvement
Presence of metastasis on complete lymphadenectomy
Time frame: one day
Clinical tumor size
Clinical measurement of the tumor in millimeters after surgery
Time frame: one day
Clinical nodal involvement
Presence of axillary lymph nodes before surgery (no versus yes)
Time frame: one day
Estrogen receptor expression status
Expression of estrogen receptors on tumor after surgery (% expression in immuno-histo-chemistry, ranging from 0 to 100%.
Time frame: one day
Progesterone receptor expression status
Expression of progesterone receptor on tumor after surgery (% expression in immuno-histo-chemistry, ranging from 0 to 100%.
Time frame: one day
HER2 status
Expression of HER2 on tumor after surgery (expression assessed by immuno-histo-chemistry, if HER2 is ++, fluorescence in situ hybridization. HER2 status is ranged to not overexpressed (0 and +), equivocal (++) and overexpressed (+++).
Time frame: one day
Sexe
Male or Female
Time frame: one day
Scarff Bloom and Richardson grade (SBR)
This grade is the addition of score of tubule formation (\>75% 1 point 10%-75% 2 point \<10% 3 points), nuclear pleomorphism (small, regular uniform cells 1 point moderate increase in size and variability 2 points, marked Variation 3 points) and mitotic counts (dependent on microscope field area 1-3 points) assessed by pathology analysis on tumor after surgery. The SBR grade is ranging from I (total of 3 to 5), II (6 and 7) and III (8 and 9).
Time frame: one day
In situ component
Presence or absence of in situ carcinoma assessed by pathology analysis on tumor after surgery
Time frame: one day
Pathological histotype
Histologic subtype of breast tumor : ductal, lobular or other, assessed by pathology analysis on tumor after complete surgery
Time frame: one day
Metastatic sites (if available)
Metastatic sites of primary breast cancer : Nodal (other than axillary), lung, liver, bone, cerebral and other sites.
Time frame: one day
Medical treatment
Type of chemotherapy (adjuvant, neoadjuvant, metastatic)
Time frame: one day
Overall Survival
The time from the date of first treatment or of first consultation, whichever comes first, to the date of death from any cause.
Time frame: one day
Invasive Disease Free Survival
The time from the date of the first treatment or th first consultation to the date of local or ipsilateral or controlateral invasive breast cancer, or other invasive cancer or distant recurrence or death from breast cancer or any cause
Time frame: one day
Distant Disease Free Survival
The time from the date of the first treatment or the first consultation to the date of distant recurrence or death from breast cancer or any cause
Time frame: one day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.